89213-87-6

Basic information

• Product Name: ANP 1-28, HUMAN
• Synonyms: ATRIAL NATRIURETIC PEPTIDE HUMAN;ATRIAL NATRIURETIC PEPTIDE HUMAN, 1-28;ATRIAL NATRIURETIC PEPTIDE 1-28, HUMAN;ATRIAL NATRIURETIC PEPTIDE (1-28), HUMAN, PORCINE;ATRIAL NATRIURETIC FACTOR 1-28, HUMAN;ATRIAL NATRIURETIC FACTOR (1-28) (HUMAN, CANINE);ATRIAL NATRIURETIC FACTOR (1-28) (HUMAN, PORCINE);ANP, ALPHA-, HUMAN
• CAS NO: 89213-87-6
• Molecular Formula: C₁₂₇H₂₀₃N₄₅O₃₉S₃
• Molecular Weight: 3080.44
• EINECS: 1312995-182-4
• Product Categories: peptide
• Mol File: 89213-87-6.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.55 g/cm³
• Refractive Index: 1.688
• CAS DataBase Reference: ANP 1-28, HUMAN(CAS DataBase Reference)
• NIST Chemistry Reference: ANP 1-28, HUMAN(89213-87-6)
• EPA Substance Registry System: ANP 1-28, HUMAN(89213-87-6)

Safety Data

• Hazardous Substances Data: 89213-87-6(Hazardous Substances Data)

Usage

Description

Different sources of media describe the Description of 89213-87-6 differently. You can refer to the following data:
1. Carperitide is the α-human atrial natriuretic peptide (α-hANP) produced by recombinant technology. It was introduced in Japan as a treatment for acute congestive heart failure (CHF). In dogs with CHF, carperitide significantly reduced the elevated left ventricular end-diastolic pressure and the index of myocardial oxygen consumption (systolic blood pressure x heart rate). In a clinical trial, carperitide was effective in improving hemodynamics and symptoms in 60% of patients with acute CHF. Carperitide was reported to be well tolerated with no significant adverse effects clinically. A beneficial effect on hemodynamics has been reported in chronic heart failure patients. Carperitide is also in clinical trials for maintenance of blood pressure during surgical operations.
2. Atrial natriuretic peptide (ANP) is an endogenous peptide generated by proteolysis of prepro-ANP that is secreted by cardiomyocytes in the heart. It has effects on the renal and cardiovascular systems that decrease vasoconstriction, inhibit renin secretion, and increase sodium excretion. Human ANP binds to ANP receptors on cultured vascular smooth muscle cells (VSMCs) with a Kd value of approximately 1-2 nM and increases cGMP levels in a dose-dependent manner. It relaxes potassium-induced contraction of isolated canine renal arterial strips when used at concentrations of 10 and 100 ng/ml and dilates renal arteries in anesthetized dogs when used at doses ranging from 10 to 100 ng/kg. In a rat model of heart failure following experimental autoimmune myocarditis, human ANP, via osmotic mini pump for 28 days, decreases cardiomyocyte size as well as the amount of cardiac fibrosis and left ventricular remodeling. ANP (1-28) (human) is a 28 amino acid peptide corresponding to the human protein sequence.

Uses

Treatment of decompensated congestive heart failure.

Brand name

Daiichi Suntory, Japan.

InChI:InChI=1/C127H203N45O39S3/c1-9-64(6)99-121(209)150-52-94(182)151-65(7)100(188)155-76(34-35-91(129)179)109(197)167-85(56-174)104(192)149-53-96(184)153-78(43-62(2)3)102(190)148-54-97(185)154-89(119(207)164-82(48-92(130)180)114(202)169-86(57-175)116(204)163-81(46-67-23-14-11-15-24-67)113(201)158-73(27-18-39-143-125(135)136)107(195)166-84(122(210)211)47-68-30-32-69(178)33-31-68)60-213-214-61-90(171-118(206)88(59-177)170-117(205)87(58-176)168-108(196)74(28-19-40-144-126(137)138)156-106(194)72(26-17-38-142-124(133)134)157-112(200)79(44-63(4)5)161-101(189)70(128)55-173)120(208)162-80(45-66-21-12-10-13-22-66)103(191)147-50-93(181)146-51-95(183)152-71(25-16-37-141-123(131)132)105(193)160-77(36-42-212-8)110(198)165-83(49-98(186)187)115(203)159-75(111(199)172-99)29-20-41-145-127(139)140/h10-15,21-24,30-33,62-65,70-90,99,173-178H,9,16-20,25-29,34-61,128H2,1-8H3,(H2,129,179)(H2,130,180)(H,146,181)(H,147,191)(H,148,190)(H,149,192)(H,150,209)(H,151,182)(H,152,183)(H,153,184)(H,154,185)(H,155,188)(H,156,194)(H,157,200)(H,158,

Upstream product

• 91917-63-4 atrial natriuretic peptide 

Relevant articles and documents

One-Pot/Sequential Native Chemical Ligation Using Photocaged Crypto-thioester

A practical and efficient methodology for the chemical synthesis of peptides/proteins using a one-pot/sequential ligation is described. It features the use of photocleavable S-protection on an N-sulfanylethylaniline moiety. Removal of the S-protecting ligated materials under UV irradiation provides a readily usable mixture for subsequent native chemical ligation.

3-Nitro-2-pyridinesulfenates as Efficient Solution- and Solid-Phase Disulfide Bond Forming Agents

In this paper, a new disulfide-forming agent based on the finding that alkoxy 3-nitro-2-pyridinesulfenates (Npys-OR) can oxidize thiol groups is reported. Methyl 3-nitro-2-pyridinesulfenate (Npys-OMe), which is easily prepared from 3-nitro-2-pyridinesulfenyl chloride in a one-step reaction and has a reduction peak potential (Epc) of ?0.541 V versus Ag/AgCl, produces the cyclic nonapeptide oxytocin from its linear form in good yield (92 %) with minimal oligomer formation. Npys-OMe in the solid phase also demonstrated excellent results in oxytocin synthesis. Other disulfide-containing peptides, such as α-human atrial natriuretic peptide and α-conotoxin ImI, were also successfully synthesized. During these syntheses, no side reactions of methionine (Met) and tryptophan (Trp) residues or the S-acetamidomethyl (Acm) protecting group were detected. These results suggested that Npys-OMe or its solid-phase analog provides a new strategy for regioselective disulfide bond formation to assist the synthesis of complex disulfide-rich peptides.